The glucagon like peptide-1 receptor (GLP-1R) agonist liraglutide attenuates induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression in human vascular endothelial cells (hVECs) in vitro and may afford protection against endothelial cell dysfunction (ECD), an early abnormality in diabetic vascular disease. Our study aimed to establish the dependence of the in vitro effects of liraglutide on the GLP-1R and characterise its in vivo effects in a mouse model of ECD. In vitro studies utilised the human vascular endothelial cell line C11-STH and enzyme-linked immunosorbent assays (ELISA) for determination of PAI-1 and VAM expression. In vivo studies of vascular reactivity and immunohistochemical analysis were performed in the ApoE -/mouse model. In vitro studies demonstrated GLP-1R-dependent liraglutide-mediated inhibition of stimulated PAI-1 and VAM expression. In vivo studies demonstrated significant improvement in endothelial function in liraglutide treated mice, a GLP-1R dependent effect. Liraglutide treatment also increased endothelial nitric oxide synthase (eNOS) and reduced intercellular adhesion molecule-1 (ICAM-1) expression in aortic endothelium, an effect again dependent on the GLP-1R. Together these studies identify in vivo protection, by the GLP-1R agonist liraglutide, against ECD and provide a potential molecular mechanism responsible for these effects.
Introduction
Type 2 diabetes is characterised by accelerated atherosclerosis. 1 Endothelial cell dysfunction (ECD) has been associated with premature atherosclerosis, is identified in type 2 diabetes, and had been postulated to be causal in the atherogenic process. 2 Diabetes-associated ECD is characterised by elevated tumour necrosis factor α (TNFα) levels [3] [4] [5] [6] [7] [8] with attendant induction of plasminogen activator inhibitor-1 (PAI-1) and vascular cell adhesion molecule (ICAM-1 and VCAM-1) expression. [3] [4] [5] [6] [7] [8] The incretin glucagon like peptide-1 (GLP-1) has a well documented role in glucose-stimulated insulin release and the preservation of plasma glucose homeostasis. 9 The importance of the incretin system in glucose homeostasis is emphasised by the recent successful therapeutic exploitation of this system utilising GLP-1 receptor (GLP-R) agonists and inhibitors of the dipetidyl pepdidase 4 (DPPIV) enzyme to overcome the extremely short half-life of native GLP-1. 10 Identification of the GLP-1R in tissues outside the pancreatic ß cell and in particular on vascular endothelial cells 11 suggests a previously unsuspected role for GLP-1 in vascular biology. In vitro native GLP-1 attenuates TNFinduced PAI-1 expression in human vascular endothelial cells. 5 In vivo studies demonstrate that native GLP-1 regulates vascular tone and endothelial function, 12, 13 and clinical studies have reported reduced endothelial dysfunction in type 2 diabetic patients with established coronary artery disease. 11 Liraglutide is an acylated GLP-1 analogue and has a half-life of 10-14 h allowing once-daily subcutaneous (s.c.) injection. 14 Clinical trials of liraglutide in patients with type 2 diabetes demonstrate improved levels of both fasting and postprandial glucose, improvement in β-cell function, a reduction in plasma glucagon concentration, weight loss, reduced blood pressure and an improvement in cardiovascular risk biomarkers. [14] [15] [16] [17] [18] Our previous in vitro studies identified liraglutide-mediated inhibition of TNFα and mild hyperglycaemia-induced PAI-1 and VAM expression in transformed hVEC cells. 19 Our current study aimed to determine the dependence of our previously established in vitro observations on the GLP-1R and extend these investigations by determining the effects of liraglutide in an in vivo model of ECD together with characterisation of the attendant molecular mechanisms responsible for these effects.
Materials and methods

Cell culture and materials
The spontaneously transformed human umbilical vein endothelial cell line C11-STH 20 was utilised in all in vitro experiments. C11-STH cells were cultured to confluence at 37°C in gelatin-coated Nunclon cell culture dishes in Media-199 supplemented with penicillin/streptomycin, 20% FCS, 20 µg/ml endothelial cell growth factor and 20 µg/ml heparin. Liraglutide was provided by Novo Nordisk A/S, Denmark. C11-STH cells were incubated under serum free conditions with liraglutide (100 nM) or the GLP-1 receptor antagonist exendin (9-39) (100 nM) alone or with 10 ng/ml TNFα for 16 h alone or in combination with liraglutide and/or exendin . ELISA assays for VCAM-1 and ICAM-1 (R&D systems, USA) were performed using conditioned medium from C11-STH cells to determine protein expression levels.
The specific PKA inhibitor H89 was purchased from Alexis (Laüfelfingen, Switzerland) and used at a concentration of 10 µM.
Reverse transcriptase PCR (RT-PCR) and real time PCR
Reverse transcriptase PCR. RT-PCR was performed on total RNA extracted from C11-STH cells as previously reported. 19 Primers used for VCAM-1 were: forward 5'-GAT-ACA-ACC-GTC-TTG-GTC-AGCCC-3'; reverse 5'-CGC-ATC-CTT-CAA-CTG-GGC-CTT-3'. Primers used for ICAM-1 were: forward 5'-CAG-TGA-CCA-TCT-ACA-GCT-TTC-CGG-3'; reverse 5'-GCT-GCT-ACC-ACA-GTG-ATG-ATGACA-A-3'. The human GAPDH gene was used as an internal control. Primers for GAPDH were: forward 5'-CCT-GCA-CCA-CCA-ACT-GCT-TAG-C-3'; reverse 5'-CCA-GTG-AGC-TTC-CCG-TCT-AGC-3'.
Real time PCR. Total RNA was extracted from C11-STH using Trizol reagent (Invitrogen). An aliquot (2 µg) of the total RNA was reverse transcribed in 20 µl reaction mixture at 50°C for 1 h. cDNA was then amplified by real-time PCR using specific primers. Primers used for NFκB subunit NFκB1 were: forward: 5'-CAG-GAA-GAT-GTG-GTG-GAG-GAT-3', reverse: 5'-TGT -CTG-GCT-CCA-CAG-CCA-GGT-3'. Results were normalised against expression of human β actin gene. Primers for β-actin were: forward: 5'-CTG-GAC-TTC-GAG-CAA-GAG-AT-3'; reverse: 5'-GAT-GTC-CAC-GTC-ACA-CTT-CA-3'.
In vivo studies
Non-diabetic male B6 apolipoprotein E-deficient (ApoE -/-) mice with a > 99% C57BL/6J background were obtained from Animal Resources Centre (Western Australia). All mice were obtained at 5 weeks of age and weighed between 25 g and 35 g at the time of experiments. At 6-8 weeks of age mice were transferred to a high fat diet (HFD) containing 22% fat and 0.15% cholesterol (Specialty Feeds, Western Australia) for a period of 12 weeks prior to, as well as during, the subsequent four week treatment period. Animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health and these were approved by the Monash University School of Biomedical Sciences Animal Ethics Committee.
Blood pressure measurement
Systolic blood pressure was measured prior to and at the end of treatment using non-invasive tail-cuff plethysmography (ADInstruments, Sydney).
Treatment protocol
ApoE -/mice were randomised to one of the following treatment groups: saline (vehicle), liraglutide (300 mg/kg twice daily, s.c. [80 nmol/kg, twice daily]), liraglutide + exendin-9 (150 pmol/kg per min). Liraglutide and its vehicle were administered twice daily via s.c injection and exendin-9 was administered s.c via mini osmotic pump. Implantation of the mini osmotic pumps occurred under general anaesthetic with ApoE -/mice anaesthetised using inhaled isoflurane and an incision made in the midscapular region through which mini osmotic pumps (Alzet model 1004, Alza Corp) were inserted for subcutaneous drug administration. Dosages of liraglutide and exendin-9 were selected based on previous in vivo study results. 21, 22 At the end of treatment, animals were anaesthetised by isoflurane inhalation and decapitated. Heart and the whole aorta were removed and placed in ice-cold Krebsbicarbonate buffer (pH 7.4) consisting of (mM): NaCl 118, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 .7H 2 0 1.2, CaCl 2 2.5, NaHCO 3 25 and glucose 11.7. The connective tissue surrounding the aorta was carefully removed under a binocular dissection light microscope (Olympus SZ40) and the abdominal aorta was dissected for vascular reactivity studies, leaving the aortic arch and thoracic aorta attached to the heart.
Vascular reactivity studies
Four aortic rings per mouse (~ 3 mm long) were obtained from the abdominal aorta and each ring was suspended between two stainless steel wires connected to an isometric force transducer (FT-03, Grass Instruments). Concentration response curves to the endothelium-dependent vasodilator acetylcholine (ACh) were constructed in tissues preconstricted with the thromboxane A 2 analogue, U46619 ([1,5,5hydroxy-11a, 9a-(epoxymethano)prosta-5Z, 13E-dienoic acid]), as previously described. 23 At the end of the acetylcholine curve, 10 mM of the endothelium-independent vasodilator, sodium nitroprusside (SNP), was added to the bath to test vascular smooth muscle integrity.
In addition, we assessed whether chronic liraglutide treatment altered basal NO levels by determining the level of contraction produced in response to the acute administration of the NO synthase inhibitor (Nω-nitro-L-arginine methyl ester) L-NAME (100 µM) in isolated abdominal aortic rings obtained from each of the chronic treatment groups with these tissues preconstricted to ~ 20-30% of maximum.
eNOS and ICAM-1 localisation
Immunohistochemical analysis of eNOS and ICAM-1 expression was assessed using frozen 10 mm thick aortic cross-sections taken from the section of aorta from ApoE -/mice immediately adjacent to segments used for vascular reactivity studies, the area known as the thoracoabdominal aorta, as previously described. 23 The frozen aortic crosssections were acetone fixed (100%) for ~ 10 min. This was followed by 30 min incubation with 10% goat-serum blocker to inhibit non-specific binding. Aortic sections were then immunostained with either a 1:500 dilution of rabbit polyclonal anti-eNOS antibody (BD Biosciences) or a 1:50 dilution of mouse monoclonal anti-ICAM-1 antibody for 2 h in a humidified chamber at room temperature. For eNOS localisation, sections were washed in Tris-buffer for ~ 30 min and incubated for 2 h with a peroxidase labelled polymer conjugated to goat anti-rabbit immunoglobulins (DAKO). Following the 2 h incubation, slides were washed in Tris-buffer once more, and then incubated with diaminobenzidine (DAB) for 5 min. For ICAM-1 immunostaining the Vectastain M.O.M Kit was used to enable detection of specific staining for ICAM-1 in mouse tissue.
All sections were rinsed in distilled water, counterstained with haematoxylin and cover slipped. Two sections (20 mm apart) for each mouse were averaged and analysed at ×20 magnification. Two blinded observers analysed eNOS staining by scoring the intensity of positive staining in an arbitrary grading system based on a scale of 1 to 5 (lowest to highest). Scores were averaged for each aortic section to allow comparison of eNOS levels between treatment groups. To quantitate the ICAM-1 immunofluorescence we used analySIS software (Soft Imaging System, Singapore) as previously described. 23 
Data analysis
All results are expressed as mean ± standard error of the mean (SEM). Statistical comparisons were by one-or twoway repeated measures ANOVA with Bonferroni corrections where appropriate using GraphPad Prism version 4.00 (GraphPad Software, San Diego, California, USA). The non-parametric statistical Kruskal-Wallis test was used for analysis of the eNOS immunohistochemistry. p < 0.05 was deemed statistically significant.
Results
Liraglutide inhibition of TNF-α induction of (a) ICAM-1 mRNA and protein and (b) VCAM-1 mRNA and protein expression is GLP-1R dependent
In vitro TNF-α induced ICAM-1 and VCAM-1 mRNA and protein expression in C11-STH hVECs at 16 h ( Figure 1, A  and B ). This effect was significantly inhibited by the addition of liraglutide. The inhibitory effect of liraglutide on TNF-α induction of ICAM-1 and VCAM-1 was attenuated by concomitant addition of exendin indicating that this effect is dependent on the GLP-1R.
Liraglutide inhibition of TNF-α induction of nuclear factor κB1 mRNA is not protein kinase A mediated
We were interested in determining the effect of liraglutide on NFκB1 mRNA expression as an additional potential liraglutide-mediated regulatory step in NFκB-mediated gene regulatory events.
In C11-STH cells liraglutide treatment inhibited TNFαmediated induction of NFκB1 mRNA expression, an effect which was identified to be independent of PKA signalling as demonstrated by use of the specific PKA inhibitor H89 (Figure 2 ).
Liraglutide inhibition of endothelial cell dysfunction in ApoE -/mice is GLP-1 receptor dependent
Ex vivo organ bath studies using isolated aortic rings taken from ApoE -/mice on a high-fat diet treated with liraglutide for four weeks demonstrated a significant improvement in endothelial function with liraglutide compared with vehicle treated mice (max relaxation: liraglutide R max = 78.45 ± 2.5% vs. saline 55.36 ± 6.89%; p < 0.01; two-way ANOVA).
The improvement in endothelial-dependent relaxation evoked by liraglutide was completely abolished in mice cotreated with exendin (9-39) (R max = 53.95 ± 6.54%) indicating that this effect is also dependent on the GLP-1R (Figure 3) . The integrity of the vascular smooth muscle cells from the aortae of animals from the treatment groups was assessed utilising exposure to SNP. All treatment groups responded equally and with maximal constriction to exposure to SNP, indicating functional vascular smooth muscle cells and confirming the vascular endothelial nature of the observed improvements in vascular reactivity with liraglutide treatment (data not shown).
In addition, we determined the effect of L-NAME induced increases in tension as an indirect measure of basal NO production (Figure 4 ). There was a trend for increased contraction due to L-NAME in the liraglutide treated group and a reversal when combined with exendin 9-39.
No significant change in blood pressure or body weight was noted in any of the treatment groups (data not shown).
Liraglutide induces endothelial eNOS and inhibits ICAM-1 expression in vivo
Immunohistochemical analysis clearly identifies a significant increase in expression of eNOS in the endothelium from liraglutide-treated mice compared with vehicletreated animals, an effect which was again abrogated by the concomitant administration of the GLP-R antagonist exendin 9-39, suggesting a GLP-1R mediated effect ( Figure 5, A  and B ). Liraglutide treatment also significantly reduced the expression of ICAM-1, an effect that was reversed with concomitant administration of the GLP-R antagonist exendin 9-39 ( Figure 6, A and B ).
Discussion
Endothelial cell dysfunction, its attendant enhanced expression of vascular adhesion molecules (VAMs) and sequelae of accelerated atherogenesis is an abnormality frequently identified in the vulnerable diabetic patient population. 2, 24 Recent evidence suggests that incretin based therapies, in addition to improvement in glycaemia control, may afford atheroprotection in type 2 diabetes via improvement in ECD. 11 Our previous studies have established the efficacy of GLP-1 and its analogue liraglutide at inhibiting cytokine and mild hyperglycaemia induced expression of vascular peptides. 5, 19 We were subsequently interested in determining the in vitro and in vivo activity of liraglutide on expression of vascular adhesion molecules and ECD together with the dependence on the GLP-1R and molecular mechanisms responsible for these effects.
Our in vitro observations suggest that liraglutide inhibits TNF-α stimulated VAM expression in human vascular endothelial cells in a GLP-1R-dependent manner. Moreover, this effect was confirmed in vivo after chronic liraglutide treatment of ApoE -/mice inhibited ICAM-1 expression. Our observations also suggest that liraglutide may be involved in a previously unrecognised mechanism of NFκB regulation pertaining to inhibition of stimulated NFκB mRNA transcription, an effect demonstrated to be independent of PKA. These results are in part supported by a recent in vitro reporter assay suggesting liraglutide-mediated inhibition of cytokine-induced NFκB transcriptional activation is PKA and GLP-1R independent, although no additional in vitro or in vivo studies to confirm the downstream effects of GLP-1R blockade were performed on cytokine induced VAM expression levels. 25 Given that VAM expression in our in vitro and in vivo systems was sensitive to exendin 9-39 administration our observations suggest liraglutide utilises the GLP-1R although may engage signalling pathways in addition to that known to utilise PKA. 9 Interestingly, PKA-independent attenuation of NFκB-dependent modulation of vascular adhesion molecules has been previously described. 26 The present in vivo data identify liraglutide-mediated, GLP-1R-dependent, inhibition of endothelial cell dysfunction in the ApoE -/mouse model, an effect which is associated with increased eNOS expression and inhibition of ICAM-1 expression in the aortic endothelium. The GLP-1 antagonist exendin-9 was given by a continuous infusion to ensure adequate GLP-1 receptor blockade, as previously described. 22 While exendin-9 was given via a different subcutaneous method of administration from that used for liraglutide, both drugs were at similar doses, with the GLP-1 receptor antagonist clearly blocking the effects of liraglutide. Interestingly, the improvement in ECD observed with liraglutide treatment of ApoE -/mice was sufficient to recapitulate the relaxation curves observed in wild type C57BL/6J mice supporting a significant effect of this agent in the setting ECD (data not shown). The potential molecular mechanisms underlying the improvement in endothelial function mediated by liraglutide suggests an anti-inflammatory activity of liraglutide, a concept supported in several recent studies utilising GLP-1 analogues. 25, 27, 28 Improvement in ECD is also associated with increased NO release, a trend observed in our in vivo studies of liraglutide treated ApoE -/mice, as evidenced by an increased contraction in response to L-NAME in the liraglutide-treated group, and extending recent in vitro studies suggesting liraglutide-mediated induction of NO production in vascular endothelial cells. 25 Our observations of enhanced in vivo eNOS expression in the aortic sections of liraglutide treated mice extend recent in vitro reports identifying enhanced eNOS phosphorylation, activity and liraglutide-mediated restoration of cytokine-induced downregulation of eNOS mRNA levels in hVECs 25 and provide a definitive mechanism for the observed in vivo trend of increased basal NO production in liraglutide treated ApoE -/mice. Recent in vitro studies suggest NFκB activation as central to the underlying molecular mechanism for liraglutide-mediated regulation of eNOS expression. 25 Interestingly, as previously mentioned, our in vitro observations identify liraglutidemediated inhibition of NFκB1 mRNA expression, which may also afford an additional, previously unsuspected, level of control in the regulation of eNOS expression. Mechanistically, regulation of NFκB gene expression is itself, in part, under the control of NFκB binding sites in the NFkB1 gene promoter 29 and suggests that inhibition of NFκB activation, via, for example, liraglutide-mediated attenuation of NFκB activation, may also result in reduced NFκB expression alleviating cytokine-mediated, NFκBdependent, suppression of eNOS expression.The in vivo sequelae of sustained ECD has been postulated to be increased atherogenesis with increased expression of attendant molecules associated with the atherosclerotic process being observed. 2 Taken together our observations demonstrate improved ECD in association with a reduction in expression of molecules associated with atherogenesis in the setting of treatment with the GLP-1 analogue liraglutide.
We provide a potential molecular mechanism for these observations involving the in vivo regulation of eNOS expression by liraglutide and postulate that these effects are likely mediated by non-PKA, GLP-1R signalling events. These possible atheroprotective effects of GLP-1 analogues warrant on-going investigations to further explore this possibility.
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